Glenview Trust co Decreases Position in Edwards Lifesciences Corporation $EW

Key Points

• Glenview Trust co reduced its stake in Edwards Lifesciences by 50.5% during the 1st quarter, selling over 180,000 shares and now holding 176,908 shares valued at approximately $12.82 million.
• Edwards Lifesciences reported $1.53 billion in revenue for the last quarter, surpassing expectations, with earnings of $0.67 per share, beating analyst estimates of $0.62.
• Analysts have recently increased their price targets for Edwards Lifesciences, with Barclays raising theirs from $90.00 to $95.00 and Royal Bank Of Canada from $85.00 to $89.00, indicating a growing confidence in the company's performance.

Glenview Trust co cut its holdings in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 50.5% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 176,908 shares of the medical research company's stock after selling 180,654 shares during the quarter. Glenview Trust co's holdings in Edwards Lifesciences were worth $12,822,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of EW. Brighton Jones LLC purchased a new stake in shares of Edwards Lifesciences in the fourth quarter valued at approximately $266,000. Bank Pictet & Cie Europe AG boosted its stake in shares of Edwards Lifesciences by 16.7% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 10,231 shares of the medical research company's stock valued at $757,000 after buying an additional 1,463 shares in the last quarter. Focus Partners Wealth raised its holdings in Edwards Lifesciences by 43.9% during the fourth quarter. Focus Partners Wealth now owns 63,380 shares of the medical research company's stock worth $5,089,000 after purchasing an additional 19,347 shares during the last quarter. Gotham Asset Management LLC raised its holdings in Edwards Lifesciences by 105.8% during the fourth quarter. Gotham Asset Management LLC now owns 16,423 shares of the medical research company's stock worth $1,216,000 after purchasing an additional 8,444 shares during the last quarter. Finally, Meridiem Capital Partners LP acquired a new position in Edwards Lifesciences during the fourth quarter worth $3,172,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, insider Larry L. Wood sold 8,950 shares of the stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the sale, the insider owned 206,900 shares of the company's stock, valued at approximately $16,150,614. This represents a 4.15% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Daniel J. Lippis sold 4,114 shares of the company's stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the completion of the sale, the vice president directly owned 22,002 shares of the company's stock, valued at $1,748,278.92. The trade was a 15.75% decrease in their position. The disclosure for this sale can be found here. 0.34% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Trading Down 0.9%

Shares of NYSE:EW traded down $0.73 during midday trading on Monday, reaching $76.85. The company's stock had a trading volume of 1,219,360 shares, compared to its average volume of 4,428,769. The firm has a market cap of $45.12 billion, a price-to-earnings ratio of 11.04, a price-to-earnings-growth ratio of 3.74 and a beta of 1.07. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 1 year low of $64.00 and a 1 year high of $83.00. The business has a 50 day moving average price of $78.92 and a 200 day moving average price of $75.45.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, beating analysts' consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The business had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same quarter in the previous year, the business earned $0.70 earnings per share. The business's revenue for the quarter was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Research analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Analysts Set New Price Targets

EW has been the subject of several research reports. Robert W. Baird lifted their price objective on Edwards Lifesciences from $78.00 to $79.00 and gave the stock a "neutral" rating in a report on Friday, July 25th. Stifel Nicolaus lifted their price objective on Edwards Lifesciences from $90.00 to $95.00 and gave the stock a "buy" rating in a report on Friday, July 25th. Wells Fargo & Company lifted their price objective on Edwards Lifesciences from $84.00 to $88.00 and gave the stock an "overweight" rating in a report on Thursday, August 7th. Royal Bank Of Canada lifted their price objective on Edwards Lifesciences from $85.00 to $89.00 and gave the stock an "outperform" rating in a report on Friday, July 25th. Finally, Evercore ISI lifted their price objective on Edwards Lifesciences from $77.00 to $80.00 and gave the stock an "in-line" rating in a report on Friday, July 25th. Three equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $86.26.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.